RxDoctor Payments Data

Katarzyna Tesz

Psychiatric/Mental Health · Berlin, CTNPI 1205593209

Payments from drug & device makers

$2,833in general payments, 2019–2025

Across 209 payments — averaging $13.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$904
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$483
  • Axsome Therapeutics, Inc.$195
  • Lundbeck LLC$189
  • Neurocrine Biosciences, Inc.$181
  • Alkermes, Inc.$180
  • plus $701 from 12 others

What the payments were for

  • Food & beverage$2,78698%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,833 in reported general payments places this provider in the 85th percentile of 679 psychiatric/mental health providers in Connecticut.

See all psychiatric/mental health providers in Connecticut

Medicare billing

Part B allowed, 2024
$14,877
Medicare patients
40
Services billed
139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl87$158,830
TrintellixVortioxetine Hydrobromide23$25,287
RexultiBrexpiprazole13$24,086
LybalviOlanzapine/Samidorphan Malate12$18,718
Clomipramine Hcl20$11,867
Aripiprazole64$6,388
Duloxetine Hcl87$5,464
VyvanseLisdexamfetamine Dimesylate13$5,233
Bupropion XlBupropion Hcl122$3,427
Venlafaxine Hcl ErVenlafaxine Hcl78$2,732
Desvenlafaxine Succinate ErDesvenlafaxine Succinate24$2,474
Lurasidone Hcl24$2,388
Vilazodone Hcl15$2,345
Quetiapine Fumarate93$2,238
Clonazepam214$2,217

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$904$158,83087 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$34$30,52036 claims
Otsuka America Pharmaceutical, Inc.Rexulti$82$24,08613 claims
Alkermes, Inc.Lybalvi$180$18,71812 claims
Almatica Pharma LLCSertraline Hcl$34$58273 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 679 psychiatric/mental health providers in Connecticut.

Other psychiatric/mental health in Berlin

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →